Quince Therapeutics, Inc. (QNCX)

The company announced on January 29, 2026, that its Phase 3 NEAT clinical trial for eDSP in A-T failed to meet its endpoints, causing a significant stock price decline. The stock price dropped from approximately $3.18 to around $0.26, a 92% decrease. Subsequently, on January 30, 2026, Citizens downgraded Quince Therapeutics, and the share price as of February 2, 2026, was $0.18, an 88.75% decline from February 3, 2025. The company intends to cease clinical development of eDSP.

As a pre-commercial biopharmaceutical company, Quince Therapeutics' revenue is primarily from financing and research grants, not product sales, making demand seasonality not applicable.

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on developing therapeutics for rare and debilitating diseases, operating within the biotechnology sector, specifically the rare disease space. Their primary product candidate is EryDex (eDSP), which uses their AIDE technology to encapsulate drugs into a patient's red blood cells for targeted delivery. The lead asset, eDSP, was in a pivotal Phase 3 clinical trial for Ataxia-Telangiectasia (A-T). The company is currently pre-commercial, generating revenue through financing and research grants.

Quince Therapeutics, Inc. is headquartered in South San Francisco, California. The Phase 3 NEAT clinical trial enrolled patients across clinical sites in the U.S., U.K., and the European Union.

Quince Therapeutics' brand reputation has been significantly impacted by the failure of the Phase 3 NEAT trial for eDSP in Ataxia-Telangiectasia, announced on January 29, 2026. This event has led to a substantial stock price collapse and analyst downgrades, negatively affecting the company's development pipeline and future prospects.

Quince Therapeutics, Inc. has a notable institutional ownership presence, with 56 institutional owners and shareholders holding 12,507,049 shares as of February 2, 2026. Major institutional shareholders include Nantahala Capital Management, LLC, Vanguard Group Inc, and Millennium Management Llc. Institutional investors collectively own 30.75% of the stock. Epiq Capital Group LLC is a significant individual shareholder, holding over 40% of the company.